Market Research Report
Myasthenia Gravis - Competitive Analysis 2019
|Published by||UnivDatos Market Insights Pvt Ltd||Product code||906194|
|Published||Content info||140 Pages
Delivery time: 1-2 business days
|Myasthenia Gravis - Competitive Analysis 2019|
|Published: June 1, 2019||Content info: 140 Pages||
Myasthenia Gravis (MG) is the prototype neuromuscular disease with the immunological pathogenesis. It is an acquired autoimmune disease affecting synaptic transmission via the neuromuscular junction mainly due to the presence of autoantibodies against the acetylcholine receptors (AChR) between the synaptic space of the skeletal muscles. It leads to an impairment of the neuromuscular transmission and corresponding clinical symptoms such as fluctuating muscle weakness and fatigability.
MG can be managed effectively with therapies that include anticholinesterase agents, rapid immunomodulatory therapies, chronic immunosuppressive agents, and thymectomy. Treatment is individualized and depends upon the age of the patient; the severity of the disease, particularly dictated by respiratory or bulbar involvement; and the pace of progression. The goals of therapy in MG are to render patients minimally symptomatic or better while minimizing side effects from medications. MG is a chronic but treatable disease, and many patients can achieve sustained remission of symptoms and full functional capacity.
Most patients need immunosuppression in addition to symptomatic therapy. Prednisolone and azathioprine represent first choice drugs, whereas several second-choice options are recommended and being considered. The marketed products for the treatment of Myasthenia Gravis include Eculizumab (Alexion Pharmaceuticals); Tacrolimus (Astellas Pharma) and Venoglobulin (Mitsubishi Tanabe Pharma Corporation).
The pipeline development for the treatment of Myasthenia Gravis is robust with approximately 15+ active products in this area. The key players involved in the development of the therapeutics include Akari Therapeutics (Coversin), Alpha Cancer Technologies (ACT-101), AnTolRx (Pre-clinical Program), Argenx (Efgartigimod), Catalyst Pharmaceuticals (Amifampridine Phosphate), CSL Behring (Human normal immunoglobulin G (IgG)), CuraVac (Myasterix), Grifols Therapeutics (IGIV-C), GT Biopharma (GTP-004), Hibernaid (HBN-1 (IV); HBN-100), Immunovant (Roivant Sciences) (RVT-1401), Momenta Pharmaceuticals (M281), Novartis (Iscalimab), Protalex (PRTX-100), Ra Pharmaceuticals (Zilucoplan), Toleranzia (Myasthenia Gravis-Tolerogen), Tolerion (TOL 3034) and UCB Pharma (Rozanolixizumab).
Majority of the drugs under development are monoclonal antibody and small molecule. The development and launch of these therapies are expected to lead to the better treatment and longer life span of the individuals with Myasthenia Gravis.